This HTML5 document contains 47 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01431/identifier/chemspider/
n6http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n15http://linked.opendata.cz/resource/drugbank/drug/DB01431/identifier/pharmgkb/
n7http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n14http://linked.opendata.cz/resource/drugbank/drug/DB01431/identifier/kegg-compound/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01431/identifier/pubchem-compound/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/resource/drugbank/drug/DB01431/identifier/pubchem-substance/
n11http://linked.opendata.cz/resource/drugbank/drug/DB01431/identifier/kegg-drug/
n17http://linked.opendata.cz/ontology/sukl/drug/
n18http://linked.opendata.cz/resource/atc/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01431/identifier/drugbank/

Statements

Subject Item
n2:DB01431
rdf:type
n3:Drug
n3:description
A synthetic steroid with progestational activity. [PubChem]
n3:group
approved
n3:indication
Allylestrenol was designed to be used for miscarriage prevention, prevention of premature labour and has been investigated for possible use in men for treatment for benign prostatic hyperplasia.
owl:sameAs
n6:DB01431 n7:DB01431
dcterms:title
Allylestrenol
adms:identifier
n9:205855 n11:D01374 n12:235905 n13:DB01431 n14:C12811 n15:PA164745307 n16:46506946
n3:mechanismOfAction
Allylestrenol is similar in structure and function to progesterone. Progesterone shares the pharmacological actions of the progestins. Progesterone binds to the progesterone and estrogen receptors. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins like Progesterone will slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH (luteinizing hormone) surge. In women who have adequate endogenous estrogen, progesterone transforms a proliferative endometrium into a secretory one. Progesterone is essential for the development of decidual tissue and is necessary to increase endometrial receptivity for implantation of an embryo. Once an embryo has been implanted, progesterone acts to maintain the pregnancy. Progesterone also stimulates the growth of mammary alveolar tissue and relaxes uterine smooth muscle. It has little estrogenic and androgenic activity.
n3:routeOfElimination
The glucuronide and sulfate conjugates of pregnanediol and pregnanolone are excreted in the urine and bile. Progesterone metabolites which are excreted in the bile may undergo enterohepatic recycling or may be excreted in the feces. Progesterone metabolites are excreted mainly by the kidneys.
n3:synonym
Allyl estrenol Allyloestrenol Perselin
n3:IUPAC-Name
n4:271B4A1F-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4A25-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4A24-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4A21-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4A22-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4A23-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4A1D-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4A1E-363D-11E5-9242-09173F13E4C5 n4:271B4A1B-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4A1C-363D-11E5-9242-09173F13E4C5
n17:hasATCCode
n18:G03DC01
n3:H-Bond-Acceptor-Count
n4:271B4A2B-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4A2C-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4A26-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4A27-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4A29-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4A28-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4A2A-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
432-60-0
n3:Bioavailability
n4:271B4A30-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4A32-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4A33-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4A34-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4A2F-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4A2E-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4A31-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4A20-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4A2D-363D-11E5-9242-09173F13E4C5